Influence of ginsenoside Rh1 and F1 on human cytochrome P450 enzymes

Planta Medica

Volumn 72, Issue 2, 2006, Pages 126-131

  Liu, Yong ^a,b   Ma, Hong ^c   Zhang, Jiang Wei ^a,b   Deng, Mai Cun ^a,b   Yang, Ling ^a  

^a DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c LIAONING NORMAL UNIVERSITY   (China)

Author keywords

Cytochrome P450; Ginsenoside; Hydrolysis products; Systemic circulation

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; GINSENG EXTRACT; GINSENOSIDE; GINSENOSIDE F 1; GINSENOSIDE RB 1; GINSENOSIDE RH 1; UNCLASSIFIED DRUG; CYTOCHROME P450; ENZYME INHIBITOR; GINSENOSIDE F1; GINSENOSIDE RH1;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL TRACT; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IC 50; MALE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GINSENG; KINETICS; LIVER MICROSOME; METABOLISM;

PANAX GINSENG;

ADULT; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; GINSENOSIDES; HUMANS; KINETICS; MALE; MICROSOMES, LIVER; PANAX;

EID: 33644553478     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-873197     Document Type: Article

References (30)

1. Zou L, Harkey MR, Henderson GL Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 2002; 71: 1579-89
2. Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 2001; 52: 587-97
3. Palmer ME, Haller C, McKinney PE, Klein-Schwartz W, Tschirgi A, Smolinske SC et al. Adverse events associated with dietary supplements: an observational study. Lancet 2003; 361: 101-6
4. Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 1999; 58: 1685-93
5. Estabrook R. An introduction to the cytochrome P450s. Mol Aspects Med 1999; 20: 5-12
6. Ansede JH, Thakker DR. High-throughput screening for stability and inhibitory activity of compounds toward cytochrome P450-mediated metabolism. J Pharm Sci 2004; 93: 239-55
7. Chang TK, Chen J, Benetton SA. in vitro effect of standardized ginseng extracts and individual ginsenosides on the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1. Drug Metab Dispos 2002; 30: 378-84
8. Henderson GL, Harkey MR, Gershwin ME, Hackman RM, Stern JS, Stresser DM. Effects of ginseng components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 1999; 65: PL209-14
9. Odani T, Tanizawa H, Takino Y. Studies on the absorption, distribution, excretion and metabolism of ginseng saponins II The absorption, distribution and excretion of ginsenoside Rg1 in the rat. Chem Pharm Bull 1983; 31: 292-8
10. Odani T, Tanizawa H, Takino Y. Studies on the absorption, distribution, excretion and metabolism of ginseng saponins III The absorption, distribution and excretion of ginsenoside Rb1 in the rat. Chem Pharm Bull 1983; 31: 1059-66
11. Xu QF, Fang XL, Chen DF. Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats. J Ethnopharmacol 2003; 84: 187-92
12. Tawab MA, Bahr U, Karas M, Wurglics M, Schubert-Zsilavecz M. Degradation of ginsenosides in humans after oral administration. Drug Metab Dispos 2003; 31: 1065-71
13. Sanderink GJ, Bournique B, Stevens J, Petry M, Martinet M. Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. J Pharmacol Exp Ther 1997; 282: 1465-72
14. Lowry OH, Roseborough NJ, Farr AL, Randall RJ. Protein measurement with the Polin phenol reagent. J Biol Chem 1951; 193: 265-75
15. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. J Pharm Sci 1998; 87: 1502-7
16. Miles JS, McLaren AW, Forrester LM, Glancey MJ, Lang MA, Wolf CR. Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem J 1990; 267: 365-71
17. Bort R, Mace K, Boobis A, Gomez-Lechon MJ, Pfeifer A, Castell J. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol 1999; 58: 787-96
18. Jones DR, Gorski JC, Hamman MA, Hall SD. Quantification of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity. J Chromatogr B 1996; 678: 105-11
19. Kim RB, O'Shea D. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther 1995; 57: 645-55
20. Waxman DJ, Attisano C, Guengerich FP, Lapenson DP. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 1988; 263: 424-36
21. Lee EH, Cho SY, Kim SJ, Shin ES, Chang HK, Kim DH et al. Ginsenoside F1 protects human HaCaT keratinocytes from ultraviolet-B-induced apoptosis by maintaining constant levels of Bcl-2. J Invest Dermatol 2003; 121: 607-13
22. Lee FC, Ko JH, Park JK, Lee JS. Effects of Panax ginseng on blood alcohol clearance in man. Clin Exp Pharmacol Physiol 1987; 14: 543-6
23. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003; 31: 815-32
24. Zhang QY, Dunbar D, Ostrowska A, Zeisloft S, Yang J, Kaminsky LS. Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 1999; 27: 804-9
25. Thorn M, Finnstrom N, Lundgren S, Rane A, Loof L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 2005; 60: 54-60
26. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002; 72: 276-87
27. Smith M, Lin KM, Zheng YP. An open trial of nifedipine-herb interactions: nifedipine with St John's wort, ginseng or Ginkgo biloba [abstract]. Clin Pharmacol Ther 2001; 69: P86
28. Hasegawa H, Sung JH, Benno Y. Role of human intestinal Prevotella oris in hydrolyzing ginseng saponins. Planta Med 1997; 63: 436-40
29. Harkey MR, Henderson GL, Gershwin ME, Stem JS, Hackman RS. Variability in commercial ginseng products: an analysis of 25 preparations. Am J Clin Nutr 2001; 73: 1101-6
30. Liu Y, Li W, Li P, Deng MC, Yang SL, Yang L. The inhibitory effect of intestinal bacterial metabolite of ginsenosides on CYP3A activity. Biol Pharm Bull 2004; 27: 1555-60